The production of peptide medications is costly primarily due to the complexity of synthesis and quality control. After synthesis, extensive purification is required to remove incomplete or incorrect sequences. Manufacturing must take place under GMP pharmaceutical conditions, with rigorous quality control including mass spectrometry and chromatographic analysis of each batch. Peptides are also chemically unstable and prone to degradation, increasing requirements for storage, formulation, and packaging.

Producing the same chemical substance can involve vastly different costs depending on whether it is sold as a medicinal product or as a research chemical. Laboratory reagents are subject to less stringent requirements, allow higher impurity levels, and require less documentation. Pharmaceutical production, by contrast, demands full batch reproducibility, sterility control (where required), pharmaceutical‑grade packaging, and compliance with regulatory transport and storage standards.

As a result, even when the chemical structure is identical, pharmaceutical‑grade production is far more complex and expensive than producing superficially similar research‑grade compounds. Manufacturers of “research chemicals,” even of the highest quality, cannot offer guarantees comparable to pharmaceutical companies, as they are not legally drug manufacturers.